和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCM 和黄医药

盘前交易 05-06 07:26:06 EDT

13.30

+0.08

+0.61%

最高13.31	最低13.16	成交量1.72万
今开13.24	昨收13.22	日振幅1.13%
总市值23.20亿	流通市值13.83亿	总股本1.74亿
成交额22.82万	换手率0.02%	流通股本1.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCM","market":"US","secType":"STK","nameCN":"和黄医药","latestPrice":13.3,"timestamp":1778011200000,"preClose":13.22,"halted":0,"volume":17245,"delay":0,"changeRate":0.006051437216338886,"floatShares":104000000,"shares":174433934,"eps":2.599995,"marketStatus":"盘前交易","change":0.08,"latestTime":"05-06 07:26:06 EDT","open":13.24,"high":13.31,"low":13.16,"amount":228222.244195,"amplitude":0.011346,"askPrice":14.75,"askSize":64,"bidPrice":11.76,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.599995,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778074200000},"marketStatusCode":1,"adr":1,"adrRate":5,"listingDate":1458187200000,"exchange":"NASDAQ","adjPreClose":13.3,"postHourTrading":{"tag":"盘后","latestPrice":13.3,"preClose":13.3,"latestTime":"18:53 EDT","volume":11,"amount":146.13,"timestamp":1778021597105,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.43581656532573154,"impliedVol":0.3056,"impliedVolPercentile":0.444},"requestUrl":"/m/hq/s/HCM","defaultTab":"news","newsList":[{"id":"2631591630","title":"和黄医药(00013)：索乐匹尼布 (sovleplenib) 用于治疗温抗体型自身免疫性溶血性贫血患者的中国新药上市申请获受理并获纳入优先审评及突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2631591630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631591630?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:10","pubTimestamp":1777457421,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，索乐匹尼布用于治疗既往至少对糖皮质激素治疗反应不佳的成人温抗体型自身免疫性溶血性贫血的患者的新药上市申请已获中国国家药品监督管理局受理，并获纳入优先审评。索乐匹尼布于2026年3月获国家药监局纳入突破性治疗品种，用于治疗温抗体型自身免疫性溶血性贫血。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK1587","BK4531","BK1191","BK1588","IPOS","00013","BK4588","BK4585","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628758495","title":"李嘉诚弃中药押创新出状况？和黄医药11倍利润暴涨靠卖资产撑场，手握3款自研肿瘤药却困于转型局｜财报异动透视镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2628758495","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628758495?lang=zh_cn&edition=full","pubTime":"2026-04-18 21:15","pubTimestamp":1776518129,"startTime":"0","endTime":"0","summary":"作为首富李嘉诚医药版图的核心落子，和黄医药（00013.HK）日前同步披露的2025年年报与2026年一季度初步业绩报告，戳破了公司财务层面的纸面繁荣。2025年全年，公司归母净利润同比暴涨11倍，看似业绩迎来历史性突破，可超九成利润均来自出售资产的一次性收益，主营业务盈利几乎原地踏步。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604183709758454.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604183709758454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00001","HCM","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626975167","title":"和黄医药：将在AACR2026年会公布HMPL-A580等新药数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2626975167","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626975167?lang=zh_cn&edition=full","pubTime":"2026-04-09 08:06","pubTimestamp":1775693177,"startTime":"0","endTime":"0","summary":"南财智讯4月9日电，和黄医药（00013.HK）发布自愿公告，公司自主研发的全球首创PI3K/PIKK-EGFR抗体靶向偶联药物（ATTC）HMPL-A580的临床前数据，以及索凡替尼联合疗法治疗小肠腺癌、阑尾癌及胰腺导管腺癌的Ib/II期研究更新结果，将于2026年4月17日至22日在美国圣迭戈举行的美国癌症研究协会（AACR）2026年年会上公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093698805369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK1588","BK4531","BK1587","HCM","BK1191","00013","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624046576","title":"交银国际：4月港股有望筑底企稳 关注AI应用、智能驾驶等","url":"https://stock-news.laohu8.com/highlight/detail?id=2624046576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624046576?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:47","pubTimestamp":1775116050,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，港股3月主要扰动并非来自基本面，而是中东地缘不确定性，在缺乏企稳条件下，指数承压。港股有望从高波动震荡阶段缓步过渡至阶段性筑底企稳。另外，中东地缘不确定性若持续，高油价对内地能源板块仍形成直接盈利支撑，同时黄金受惠全球避险情绪与美元压力，维持战略性高配。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0128522157.USD","LU1051768304.USD","BK1144","LU1115378108.SGD","BK1191","SG9999002828.SGD","BK1597","SG9999011746.SGD","LU0640798160.USD","BK1256","LU0359202008.SGD","LU0163747925.USD","LU0029875118.USD","BK1098","LU0228659784.USD","BK1521","LU0471298777.SGD","LU1023057109.AUD","LU0385154629.USD","LU0048580855.USD","00778","00013","IE0031814852.USD","LU0259732245.USD","02319","LU0287142896.SGD","BK1589","LU1439103000.SGD","LU0072462343.USD","LU1048588211.SGD","LU0543330483.HKD","LU0320764755.SGD","BK1587","BK4588","LU0359201612.USD","LU0823426480.USD","02525","LU0651946864.USD","LU0594300419.USD","IE00B067MR52.USD","LU0307460666.USD","IE00B0169L03.USD","HK0000320223.HKD","BK4585","LU0650527681.SGD","IE00B031J352.USD","AVGO","LU1102505762.USD","IE00B97KM107.HKD","HSAI","LU0315179316.USD","LU1102505929.USD","CIADY","LU0251143458.SGD","LU0588546209.SGD","HK0000306685.HKD","LU1224709979.USD","LU2045819591.USD","LU0328353924.USD","LU0211977185.USD","LU0228367735.SGD","LU0348788117.USD","BK1237","IE0008368742.USD","IE0009570106.USD","HCM","300274","LU0370786039.SGD","IE0032834883.USD","HK0000306701.USD","LU0672654166.SGD","LU1515016050.SGD","LU2125910500.SGD","IE0008369823.USD","IE00B031HY20.USD","LU0173614495.USD","LU1769817179.HKD","BK1588","LU0737861699.HKD","LU0106959298.USD","LU0359201885.HKD","HK0000320264.USD","BK1553","IE00B29SXG58.USD","LU0823426308.USD","NVDA","BK1147","LU0326950275.SGD","LU1769817096.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621747577","title":"和黄医药(00013)启动HMPL-760用于治疗复发/难治性弥漫性大B细胞淋巴瘤的中国III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2621747577","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621747577?lang=zh_cn&edition=full","pubTime":"2026-03-23 08:08","pubTimestamp":1774224537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，本公司今日宣布在中国启动HMPL-760联合R-GemOx 方案用于治疗复发/难治性弥漫性大 B细胞淋巴瘤患者的注册性III期临床试验。该研究是一项随机、双盲、阳性对照的III期临床研究，旨在评估HMPL-760联合R-GemOx方案对比安慰剂联合RGemOx方案用于治疗既往接受过一线系统化疗、免疫治疗或免疫化疗联合治疗后复发或难治性且不适合移植的弥漫性大B细胞淋巴瘤患者的疗效、安全性和药代动力学。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK1191","BK4588","HCM","BK4134","00013","BK4531","III","BK4585","BK1588","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618890662","title":"中金：维持和黄医药(00013)跑赢行业评级 目标价30港币","url":"https://stock-news.laohu8.com/highlight/detail?id=2618890662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618890662?lang=zh_cn&edition=full","pubTime":"2026-03-12 10:26","pubTimestamp":1773282385,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑到和黄医药营运效率和盈利能力不断提高，上调2026年净利润预测59%至5,539万美元，引入2027年净利润预测8,891万美元。该行维持跑赢行业评级，基于DCF模型，维持目标价30港币不变，较当前股价有36.5%的上行空间。中金主要观点如下：2025年业绩符合该行预期公司公布2025业绩：收入5.49亿美元，同比-13%;其中肿瘤免疫板块综合收入2.85亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618109952","title":"紧急召回！和黄医药明星抗癌药突遭撤市","url":"https://stock-news.laohu8.com/highlight/detail?id=2618109952","media":"深圳商报·读创","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618109952?lang=zh_cn&edition=full","pubTime":"2026-03-11 00:06","pubTimestamp":1773158781,"startTime":"0","endTime":"0","summary":"3月9日，和黄医药（中国）有限公司（简称“和黄医药”或“本公司”）发布公告，宣布对旗下上市仅满一年的肿瘤创新药他泽司他（商品名：达唯珂?）启动在中国内地、中国香港和中国澳门撤市并召回该产品，同时停止所有正在进行中的他泽司他的临床试验。现有患者应立即咨询主治医生，以讨论治疗选择。公告称，此次撤市预计不会影响本公司的财务指引。2025年，和黄医药的达唯珂?的销售额为250万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113667856575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","00013","BK4531","BK1587","BK1588","BK1191","BK4585","HCM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618954412","title":"当年报披露遭遇商业化品种撤市，和黄医药(00013)何时打破“200亿估值魔咒”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618954412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618954412?lang=zh_cn&edition=full","pubTime":"2026-03-10 23:27","pubTimestamp":1773156440,"startTime":"0","endTime":"0","summary":"3月5日，和黄医药披露公司2025年年报业绩，其中公司当期股东应占溢利同比增长1111.03%，表现亮眼。根据财报，在和黄医药当期的4.57亿美元净利润中，有4.16亿美元来自出售上海和黄药业45%股权带来的收益。交易完成后，和黄医药仅持有上海和黄药业5%的股权。而在同一时间，现有品种的撤市，或许成为影响和黄医药估值的一个利空因素。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4007","BK4588","BK4531","HCM","BK1191","BK1588","BK1587","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618333029","title":"华源证券：维持和黄医药(00013)“买入”评级 ATTC平台管线潜力可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2618333029","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618333029?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:42","pubTimestamp":1773132163,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华源证券发布研报称，预计和黄医药2026-2028年公司总收入为6.32、7.71、8.90亿美元。公司海外商业化进展稳健，ATTC平台管线潜力可期，维持公司“买入”评级。华源证券主要观点如下：事件2026年3月5日，和黄医药公布2025年全年业绩：2025年全年，公司营业总收入为5.49亿美元，同比下降12.96%；公司净利润为4.57亿美元，同比增长1111.03%。公司正积极寻求和跨国制药公司合作开发相关ATTC候选药物的潜在机会，未来可期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","HCM","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618987356","title":"【券商聚焦】交银国际维持和黄医药(00013)买入 指ATTC的潜在BD交易机会值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2618987356","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618987356?lang=zh_cn&edition=full","pubTime":"2026-03-10 15:47","pubTimestamp":1773128839,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指出，和黄医药 2025年产品销售在2H25如期实现复苏，全年实现可持续的盈利。2H25肿瘤产品收入呈现重要反弹趋势，环比1H25提升16%。全年实现净利润4.57亿美元，其中包含出售上海和黄药业45%股权所获得的税后收益4.16亿美元，剔除该一次性收益后，公司仍实现了可持续的盈利。该机构认为，随着更多临床前和早期临床数据逐步产生，ATTC的潜在BD交易机会值得期待。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976234","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4531","BK1191","BK1587","BK4588","BK1147","03329","00013","HCM","BK1588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618985668","title":"潜在风险可能已超过患者潜在获益，和黄医药紧急召回上市不足一年的抗癌新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2618985668","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618985668?lang=zh_cn&edition=full","pubTime":"2026-03-10 13:34","pubTimestamp":1773120854,"startTime":"0","endTime":"0","summary":"此次突发撤市、召回的导火索，源于该药的一项海外临床研究。根据益普生的通报，该研究的独立数据监察委员会在审查了SYMPHONY-1研究的最新数据后建议，基于继发性血液系统恶性肿瘤的不良事件，该治疗方案的潜在风险可能已超过患者的潜在获益。Epizyme为达唯珂在中国的药品上市许可持有人。虽然，和黄医药公告指出，此次撤市预计不会影响其财务指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773120681548363917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4007","BK1191","BK4588","HCM","00013","BK4531","BK4585","BK1588","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618987798","title":"达唯珂折戟，创新药研发安全红线再敲警钟","url":"https://stock-news.laohu8.com/highlight/detail?id=2618987798","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618987798?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:14","pubTimestamp":1773105251,"startTime":"0","endTime":"0","summary":"达唯珂由法国药企益普生旗下Epizyme开发，为全球同类首创的EZH2甲基转移酶抑制剂。达唯珂是全球首个且唯一获批用于滤泡性淋巴瘤的口服EZH2抑制剂。此次产品撤市、相关临床试验全面终止后，该细分领域精准治疗方案的空白将再次凸显，临床未满足需求亟待新一代创新药填补。2025年4月，公司以6.085亿美元现金出售上海和黄药业45%股权，仅保留5%股权，全面聚焦创新药研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310091707a45cda1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310091707a45cda1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0963586101.USD","BK4585","IE00BMG7P694.USD","IE0034235188.USD","LU1228905037.USD","LU1880398471.USD","BK4187","ES","BK4081","CRS","LU0390134368.USD","BK4588","IE00BMQBXF63.USD","IE00BZ18W456.USD","IE0009354923.USD","HCM","ORR","BK4531","BK4006","BK4211","IE00B29SXL02.USD","IE00BMG7P819.SGD","LU1228905540.USD","IE00B66KJ199.SGD","IE00BMG7P926.USD","BK4106","PFS","LU0545562505.USD","IE0031619046.USD","BK4226","LU1803068623.USD","LU2065731478.USD","IE00BZ18W340.USD","LU1883839398.USD","BK4195","BR","LU2449327464.USD","IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4548","LU1880398554.USD","BK4007","IE00BMG7P587.USD","IE00B29SXK94.USD","LU2637428348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618360871","title":"和黄医药紧急宣布召回一款重磅肿瘤创新药；英硅智能与Liquid AI发布轻量科研基础模型 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2618360871","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618360871?lang=zh_cn&edition=full","pubTime":"2026-03-10 07:09","pubTimestamp":1773097780,"startTime":"0","endTime":"0","summary":"｜2026年3月10日星期二｜NO.1和黄医药紧急宣布召回一款重磅肿瘤创新药3月9日晚间，和黄医药公告称，其氢溴酸他泽司他片（商品名：达唯珂）的合作方益普生（Ipsen）已通知和黄医药正在美国自愿撤市该药，因此已采取措施在中国启动撤市及产品召回程序。和黄医药已随即启动在内地、香港和澳门撤市并召回该产品，并停止所有正在进行中的达唯珂的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103666571762.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103666571762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1191","BK4007","BK4585","BK4588","159992","BK1515","BK4531","06978","00013","159938","09939","HCM","BK1588","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618624731","title":"和黄医药引进抗癌药不足一年撤市召回：风险或超过获益 去年销售额250万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618624731","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618624731?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:58","pubTimestamp":1773064734,"startTime":"0","endTime":"0","summary":"在国内附条件批准不到一年，和黄医药从外部引进的一款抗癌药启动撤市及召回程序，并在全国撤网，还被移出首版商保创新药目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603093666384183.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666384183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","HCM","BK4531","BK1588","BK1587","BK4588","BK4585","BK4007","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618984644","title":"和黄医药(00013)：已启动达唯珂®撤市及产品召回程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2618984644","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618984644?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:34","pubTimestamp":1773048859,"startTime":"0","endTime":"0","summary":"益普生已通知和黄医药，其正在美国自愿撤市达唯珂。因此，已采取措施在中国启动撤市及产品召回程序。和记黄埔医药(上海)有限公司已随即启动在中国内地、中国香港和中国澳门撤市并召回该产品，并停止所有正在进行中的他泽司他的临床试验。在获悉该信息后，和记黄埔医药(上海)有限公司立即对此产品采取锁库措施，暂停全部销售和发货，并通知医疗机构停止处方及药房停止售卖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"和黄医药(00013)：已启动达唯珂®撤市及产品召回程序","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK1588","BK4531","BK1587","HCM","BK1191","00013","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618435146","title":"大行评级丨里昂：和黄医药去年业绩好坏参半，目标价降至30.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618435146","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618435146?lang=zh_cn&edition=full","pubTime":"2026-03-09 15:27","pubTimestamp":1773041223,"startTime":"0","endTime":"0","summary":"里昂发表研报指，和黄医药2025年业绩好坏参半，受商业不利因素影响，销售额低于预期，惟净利润高于预期。2026年肿瘤业务指引暗示着商业复苏即将到来，而新的ATTC产品线将成为未来几年业绩增长的关键驱动力。该行将集团今年和明年销售额预测分别调整为降21%和降16%，各年净利润预测则调整为降50%及降27%；目标价由31.4港元下调至30.4港元，维持“跑赢大市”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260309/32054050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["00013","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618480656","title":"里昂：降和黄医药(00013)目标价至30.4港元 评级“跑赢大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2618480656","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618480656?lang=zh_cn&edition=full","pubTime":"2026-03-09 15:09","pubTimestamp":1773040152,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，将和黄医药(00013)今年和明年销售额预测分别调整为降21%和降16%，各年净利润预测则调整为降50%及降27%，其目标价由31.4港元下调至30.4港元，维持评级为“跑赢大市”。和黄医药2025年业绩好坏参半，其中受商业不利因素影响，其中销售额低于预期，惟净利润高于预期。该行指，2026年肿瘤业务指引暗示著商业复苏即将到来，而新的ATTC产品线将成为未来几年业绩增长的关键驱动力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617968927","title":"剥离资产、加码创新，和黄医药能否实现突围？","url":"https://stock-news.laohu8.com/highlight/detail?id=2617968927","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617968927?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:55","pubTimestamp":1772790937,"startTime":"0","endTime":"0","summary":"3月5日晚间，和黄医药发布2025年全年业绩，全年总收入5.49亿美元，同比下降12.96%；净利润则达4.57亿美元，同比大幅增长1111.03%，已连续三年实现盈利。在市场销售额方面，和黄医药全年达5.25亿美元，其中中国以外营收达3.66亿美元，比去年增长26%，但受多重因素影响，其在国内的营收同比下降25%至1.59亿美元，拖累整体收入表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603063664590640.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603063664590640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00013","BK4585","BK4007","HCM","BK1191","BK1588","BK4531","BK4588","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617832796","title":"和黄医药(00013)：言思雅将获委任为高级兼首席独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2617832796","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617832796?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:40","pubTimestamp":1772786433,"startTime":"0","endTime":"0","summary":"就莫教授拟退任一事，董事会已批准对公司董事委员会及高级兼首席独立非执行董事的组成作出以下变动，自股东周年大会结束时起生效，惟有关董事须于股东周年大会上获股东重选为董事：言思雅医生将获委任为高级兼首席独立非执行董事，以及获委任为提名委员会主席;胡朝红博士将获委任为技术委员会主席;及陈邵文教授将获委任为可持续发展委员会成员。言思雅医生、胡博士及陈教授目前均为公司独立非执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4007","BK1587","00013","BK4585","BK4531","BK4588","HCM","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617502318","title":"大华继显：降和黄医药(00013)目标价至26港元 去年业绩符预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2617502318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617502318?lang=zh_cn&edition=full","pubTime":"2026-03-06 13:47","pubTimestamp":1772776036,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大华继显发布研报称，发表报告指，由于研发进展顺利，预期和黄医药(00013)未来数年将有新一波药品获批。维持“买入”评级，目标价由32.5港元下调至26港元，以反映地缘政治风险上升。和黄医药2025年业绩符合预期。总收入同比下降13%，但受惠于海外市场持续增长及中国销售重组的积极影响，Fruquintinib上市后销售额同比显著回升。公司目标在肿瘤学/免疫学领域实现3.3亿至4.5亿美元收入，受惠持续销售复苏。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0213},{"period":"1month","weight":-0.1375},{"period":"3month","weight":-0.1001},{"period":"6month","weight":-0.1392},{"period":"1year","weight":-0.1204},{"period":"ytd","weight":-0.0023}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":-0.03068},{"month":2,"riseRate":0.4,"avgChangeRate":0.01065},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00847},{"month":4,"riseRate":0.454545,"avgChangeRate":0.024272},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.064215},{"month":6,"riseRate":0.7,"avgChangeRate":0.077435},{"month":7,"riseRate":0.6,"avgChangeRate":0.053079},{"month":8,"riseRate":0.4,"avgChangeRate":0.002476},{"month":9,"riseRate":0.5,"avgChangeRate":-0.017634},{"month":10,"riseRate":0.5,"avgChangeRate":-0.007604},{"month":11,"riseRate":0.7,"avgChangeRate":0.110086},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016892}],"exchange":"NASDAQ","name":"和黄医药","nameEN":"Hutchison China Meditech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,HCM,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}